U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation

Immunotherapy targeting programmed cell death-1 (PD-1) induces durable antitumor efficacy in many types of cancer. However, such clinical benefit is limited because of the insufficient reinvigoration of antitumor immunity with the drug alone; therefore, rational therapeutic combinations are required...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Clin Invest
Main Authors: Haratani, Koji, Yonesaka, Kimio, Takamura, Shiki, Maenishi, Osamu, Kato, Ryoji, Takegawa, Naoki, Kawakami, Hisato, Tanaka, Kaoru, Hayashi, Hidetoshi, Takeda, Masayuki, Maeda, Naoyuki, Kagari, Takashi, Hirotani, Kenji, Tsurutani, Junji, Nishio, Kazuto, Doi, Katsumi, Miyazawa, Masaaki, Nakagawa, Kazuhiko
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society for Clinical Investigation 2019
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6934205/
https://ncbi.nlm.nih.gov/pubmed/31661465
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI126598
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים